An Open, Parallel, Single-dose Phase I Clinical Study to Evaluate the Pharmacokinetics and Safety of TQD3606 for Injection in Subjects With Renal Insufficiency
Latest Information Update: 12 Jan 2026
At a glance
- Drugs Avibactam/meropenem (Primary)
- Indications Bacterial infections
- Focus Pharmacokinetics
- Sponsors Chia Tai Tianqing Pharmaceutical Group
Most Recent Events
- 09 Jan 2026 Status changed from not yet recruiting to completed.
- 07 Nov 2024 New trial record